Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Bevacizumab (Avastin) Therapy for Exudative Neovascular Age-Related Macular Degeneration (BEAT-AMD-Study)
2005-001722-92Phase 2Completed
- Sponsor
- Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in age-related macular degeneration (AMD), sponsored by Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie. Primary endpoint: Primary: 24-week treatment duration and ocular response. Started Oct 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2005-001722-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001722-92.